Lukas Biomedical Inc.
Lukas Biomedical Inc. engages in the wholesale and retail of cosmetics in Taiwan. The company operates through E-Commerce Department, Medical Management Business, Cell Products Department, and Pharmaceutical Market Development Department segments. It also researches and develops immune cell medical technology for regenerative medicine and adjuvant treatment; engages in clinical trials; distribute… Read more
Lukas Biomedical Inc. (6814) - Net Assets
Latest net assets as of June 2025: NT$283.31 Million TWD
Based on the latest financial reports, Lukas Biomedical Inc. (6814) has net assets worth NT$283.31 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$452.48 Million) and total liabilities (NT$169.17 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$283.31 Million |
| % of Total Assets | 62.61% |
| Annual Growth Rate | 1.57% |
| 5-Year Change | 12.01% |
| 10-Year Change | N/A |
| Growth Volatility | 11.55 |
Lukas Biomedical Inc. - Net Assets Trend (2019–2024)
This chart illustrates how Lukas Biomedical Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Lukas Biomedical Inc. (2019–2024)
The table below shows the annual net assets of Lukas Biomedical Inc. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$325.82 Million | +16.31% |
| 2023-12-31 | NT$280.13 Million | -14.46% |
| 2022-12-31 | NT$327.49 Million | +14.24% |
| 2021-12-31 | NT$286.68 Million | -1.44% |
| 2020-12-31 | NT$290.88 Million | -3.50% |
| 2019-12-31 | NT$301.42 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lukas Biomedical Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15566300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$418.74 Million | 128.52% |
| Other Components | NT$90.07 Million | 27.64% |
| Total Equity | NT$325.82 Million | 100.00% |
Lukas Biomedical Inc. Competitors by Market Cap
The table below lists competitors of Lukas Biomedical Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Concorde International Group Ltd Class A Ordinary Shares
NASDAQ:CIGL
|
$10.13 Million |
|
Orefinders Resources Inc
OTCQB:ORFDF
|
$10.14 Million |
|
Mtag Group Berhad
KLSE:0213
|
$10.14 Million |
|
VIRGIN WINES UK LS -01
F:3RW
|
$10.14 Million |
|
Kavango Resources Plc
PINK:KVGOF
|
$10.13 Million |
|
META WOLF AG INH O.N.
F:WOLF
|
$10.12 Million |
|
ReFuels N.V.
OL:REFL
|
$10.12 Million |
|
Beryl 8 Plus Public Company Limited
BK:BE8
|
$10.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lukas Biomedical Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 280,132,000 to 325,821,000, a change of 45,689,000 (16.3%).
- Net loss of 94,378,000 reduced equity.
- New share issuances of 140,000,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-94.38 Million | -28.97% |
| Share Issuances | NT$140.00 Million | +42.97% |
| Other Changes | NT$67.00K | +0.02% |
| Total Change | NT$- | 16.31% |
Book Value vs Market Value Analysis
This analysis compares Lukas Biomedical Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.26x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.03x to 3.26x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$8.84 | NT$26.75 | x |
| 2020-12-31 | NT$8.79 | NT$26.75 | x |
| 2021-12-31 | NT$8.67 | NT$26.75 | x |
| 2022-12-31 | NT$8.85 | NT$26.75 | x |
| 2023-12-31 | NT$7.60 | NT$26.75 | x |
| 2024-12-31 | NT$8.22 | NT$26.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lukas Biomedical Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -49.72%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 1.46x
- Recent ROE (-28.97%) is below the historical average (-14.06%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -2.32% | -4.57% | 0.27x | 1.85x | NT$-37.13 Million |
| 2020 | -3.62% | -5.81% | 0.35x | 1.80x | NT$-39.63 Million |
| 2021 | -17.26% | -31.40% | 0.30x | 1.85x | NT$-78.16 Million |
| 2022 | -15.29% | -27.10% | 0.39x | 1.46x | NT$-82.82 Million |
| 2023 | -16.90% | -20.43% | 0.53x | 1.57x | NT$-75.37 Million |
| 2024 | -28.97% | -49.72% | 0.40x | 1.46x | NT$-126.96 Million |
Industry Comparison
This section compares Lukas Biomedical Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,107,525,400
- Average return on equity (ROE) among peers: 2.82%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lukas Biomedical Inc. (6814) | NT$283.31 Million | -2.32% | 0.60x | $10.13 Million |
| Synbio Tech Inc. (1295) | $942.97 Million | 12.01% | 1.00x | $21.72K |
| Apex Biotechnology Corp (1733) | $842.42 Million | 19.18% | 0.14x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $875.36 Million | 7.09% | 0.89x | $129.07 Million |
| Panion & BF Biotech Inc (1760) | $278.86 Million | -14.55% | 2.31x | $123.88 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $2.02 Billion | 5.81% | 0.71x | $42.95 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.16 Billion | 13.75% | 0.60x | $45.13 Million |
| Level Biotechnology (3118) | $498.78 Million | 7.80% | 0.36x | $22.63 Million |
| GenMont Biotech Inc (3164) | $861.62 Million | 3.30% | 0.66x | $31.27 Million |
| Medigen Biotechnology (3176) | $3.18 Billion | -14.68% | 0.53x | $100.57 Million |
| Sagittarius Life Science (3205) | $419.76 Million | -11.56% | 0.24x | $56.40 Million |